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Abstract Encephalomyocarditis virus (EMCV) can
infect a wide range of vertebrate species including swine
and non-human primates, but few data are available for
humans. We therefore wanted to gain further insight into
the mechanisms involved in EMCV infection of human
cells. For this purpose, we analyzed the permissiveness of
primary human cardiomyocytes towards two strains of
EMCV; a pig myocardial strain (B279/95) and a rat strain
(1086C). In this study, we show that both strains produc-
tively infect primary human cardiomyocytes and induce
complete cytolysis. Binding and infection inhibition
experiments indicated that attachment and infection are
independent of sialic acid and heparan sulfate for B279/95
and dependent for 1086C. Sequence comparison between
the two strains and three-dimensional analysis of the capsid
revealed that six of the seven variable residues are surface-
exposed, suggesting a role for these amino acids in binding.
Moreover, analysis of variants isolated from the 1086C
strain revealed the importance of lysine 231 of VP1 in the
attachment of EMCV to cell-surface sialic acid residues.
Together, these results show a potential for EMCV strains
to use at least two different binding possibilities to initiate
infection and provide new insights into the mechanisms
involved in primary human cell recognition by EMCV.
Introduction
Encephalomyocarditis virus is a single-stranded positive-
polarity RNA cardiovirus belonging to the family Picor-
naviridae. It can naturally infect a wide range of vertebrate
species including swine and non-human primates [1, 11,
13, 16, 26], reptiles and insects [9]. Rodents are considered
to be natural hosts of EMCV and are thought to be the
primary reservoir and disseminators of the virus [28]. The
primary route of transmission for EMCV is believed to be
fecal-oral [33]. Transplacental vertical transmission is
reported to occur naturally in swine and baboon [13].
Whether such infections remain asymptomatic or produce
clinical symptoms depends on many factors, including the
virus strain, the infected species, the viral dose, and the age
and immune status of the infected animal. EMCV infection
causes acute myocarditis and sudden death in piglets, and
reproductive failure in sows [19, 21]. Infection of older
pigs is asymptomatic. While it is generally asymptomatic
in rodents, EMCV can cause insulin-dependent diabetes
mellitus and nervous disorders in mice [6]. The virus has
been isolated from various organs, including heart, tonsils,
kidney, lungs, liver, spleen, small intestine and mesenteric
lymph nodes, from naturally and experimentally infected
animals [9, 24]. The target organ involved in the infection
is also dependent on the species and viral strain.
EMCV has rarely been recognized as a cause of human
illness. Strains of EMCV have been reported from chil-
dren suffering from aseptic meningitis, poliomyelitis-like
disease and Guillain-Barre´ syndrome, although a causal
relationship between EMCV and the symptoms has not
been established [10]. An accidental infection by Mengo
virus occurred in a man who cared for a paralyzed
cynomolgus macaque. The patient developed signs of
acute encephalitis, and virus was recovered from his
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serum [9]. Several serological studies have shown the
presence of antibodies against EMCV in the healthy
human population, suggesting that human EMCV infec-
tion is relatively common, but most cases are asymp-
tomatic or unrecognized [7, 17, 30]. In vitro studies have
shown that primary human cardiomyocytes are permissive
to an EMCV MN-30 strain previously isolated from an
aborted pig foetus. On the other hand, human renal epi-
thelial cells, aortic endothelial cells, bone marrow pro-
genitor cells, peripheral blood mononuclear cells and
hepatocytes were non-permissive to this strain [4]. Other
reports have described ultrastructural alterations of cul-
tured human fetal pancreatic cells or of tissue cultures
from human foetal brain infected with two variants of
EMCV (M and E) [2, 31]. However, a difference in vir-
ulence between the two variants has been observed.
Indeed, 100 plaque-forming units (PFU) were sufficient to
induced alterations of pancreatic cells with the M variant
while 10 000 PFU were needed with the E variant to
induce similar alterations. These observations suggest that
susceptibility of human cells to EMCV infection may
vary according to the cell type and to the strain or the
variant.
The first step in any infection process is the attachment
of the virus to a cell-membrane molecule representing the
cellular receptor or co-receptor for the virus. This virus-
cell interaction is considered a major determinant of viral
host range, tissue tropism and pathogenesis. The mecha-
nisms by which EMCV binds to and enters permissive
human cells are not well understood. EMCV is believed
to bind to non-permissive human erythrocytes by inter-
action with sialic acid residue of glycophorin A, the major
sialoglycoprotein of the erythrocyte surface membrane
[5, 29]. Jin et al. [14] reported the identification of a cell
surface 70-kDa sialoglycoprotein as an attachment mole-
cule for EMCV on two human permissive cell lines, HeLa
and K562. These data suggest a role of sialic acid in
EMCV binding to human cell lines. Whether sialic acid is
also involved in EMCV attachment to permissive primary
human cells or to other cell types remains to be estab-
lished. Furthermore, it is known that strains or variants of
picornaviruses can use different cell-surface molecules for
attachment. For example, strains of the two neuroviru-
lence groups of Theiler’s virus, another cardiovirus, use
different carbohydrate co-receptors for attachment: hepa-
ran sulfate for high-neurovirulence strains and sialic acid
for the low-neurovirulence strains [27]. Therefore, it is
reasonable to expect that strains or variants of EMCV that
induce different pathologies may use different molecules
to initiate infection.
To gain further insight into the mechanisms involved
in EMCV infection of human cells, we analyzed the
permissiveness of primary human cardiomyocytes towards
two strains of EMCV: a pig myocardial strain (B279/95)
and a rat strain (1086C). We report here that the two
strains productively infect human cardiomyocytes but
differ in their virulence. This difference in virulence is
likely due to their binding efficiency. We analyze the cell-
surface molecules implicated in their attachment and
show that the two strains use different mechanisms to
initiate infection, demonstrating the flexibility of EMCV
in receptor usage.
Materials and methods
Cell culture
Cryopreserved primary human cardiomyocytes (CMC)
were obtained from Clonetics (Cambrex, ref CC-2582) and
used at the first or second passage. The cells were grown in
the media and under the conditions recommended by the
manufacturer.
Virus stocks
EMCV strains were kindly provided by Dr. Frank Koenen
(Department of Virology, Section of Epizootic Diseases,
CODA-CERVA, Groeselenberg 99, B-1180 Ukkel Bel-
gium). The B279/95 strain was isolated from a piglet that
died of myocarditis [20]; the 1086C strain was isolated
from a rat (Dr. Frank Koenen, personal communication).
The two strains were propagated on BHK-21 cells. Vari-
ants of the 1086C strain were isolated by limiting dilution
in 96-well plates of BHK-21 cells. Each variant was sub-
jected to five passages on BHK-21 cells, and virus stocks
were prepared as clarified lysates as described previously
[12].
Virus titration
Virus titer was determined by plaque assays using a BHK-
21 cell monolayer. Cells were seeded in 35-mm dishes
(1.5 9 105 cells) for 24 h at 37 C. Medium was then
removed, 0.5 ml of serial 10-fold dilutions of virus sus-
pension was added, and the cells were incubated for 1 h at
37 C. Subsequently, supernatant was removed and 2 ml of
MEM containing 2% FBS, 1 mM sodium pyruvate,
0.1 mM non-essential amino acids and 1.5% low-melting-
point agarose were added. The dishes were incubated at
37 C for 3 days and stained with crystal violet solution
containing 4% paraformaldehyde. After removal of the
agarose plug, plates were washed with water. Virus con-
centrations were determined as PFU ml-1.
44 S. Hammoumi et al.
123
Reagents
Neuraminidase from Vibrio cholerae, heparinase I and
heparinase III from Flavobacterium heparinum, and hep-
aran sulfate (HS) were obtained from Sigma. Heparinase I
and III were diluted in PBS with Ca2? and Mg2? con-
taining 0.01% BSA. Anti-EMCV monoclonal antibody
(mAb) 16E4 was produced in our laboratory. Goat anti-
mouse immunoglobulin G (IgG)-fluorescein isothiocyanate
(FITC) conjugate was obtained from Biosys.
Human cell infection
Virus production was analyzed by infection of subconfluent
CMC cells in 96-well plates at a multiplicity of infection
(MOI) of 1000 PFU per cell. Virus was allowed to adsorb for
1 h at 4 C. Then, the monolayer was washed twice with PBS
and incubated with 100 ll of cell culture medium at 37 C
under a 5% CO2 atmosphere. At 0, 2, 4, 6, 8, 16 and 24 hours
postinfection (h.p.i.), one plate was frozen for virus titration.
At the end of the experiment, the plates were subjected to
another round of freeze-thawing to release intracellular
virus, and the virus titer in each well was determined on a
BHK-21 cell monolayer as described above.
For analysis of infection, subconfluent CMC cells in
24-well plates were infected at different MOI. After 1 hour
of adsorption at 37 C, cell monolayers were washed with
PBS and 1 ml of cell culture medium was added before
incubation at 37 C in a 5% CO2 atmosphere. Plates were
observed for cytopathic effect at 24 h.p.i., and cell viability
was evaluated by colorimetric assay using cell proliferation
reagent WST-1 (Roche). Briefly, at 24 h.p.i., 100 ll of
WST-1 was added to each well. After 2 h of incubation at
37 C in a 5% CO2 atmosphere, the plates were shaken
vigorously for one minute, and the absorbance of the wells
was read using a microplate reader (ELISA). Cell viability
was calculated as a percentage of uninfected cell controls.
Cell binding assays
Cells were maintained on ice during all of the reactions in
order to inhibit virus uncoating, and cold solutions were
used. Binding of virus to cells was determined using flow
cytometry as described previously [12]. Cells were seeded
in 24-well plates (106 cells per well), washed three times
with PBS and incubated with virus for 1 h whilst being
agitated. Unbound virus was removed by washing three
times with PBS, and cells were incubated with anti-EMCV
16E4 mAb for 30 min whilst being agitated. After two
washes with PBS and one with PBS containing 0.05%
Tween 20, the cells were incubated with goat anti-mouse
IgG-FITC conjugate for 30 min whilst being agitated. Cells
were rinsed twice with PBS containing 0.05% Tween 20
and once with PBS. The cells in each well were then
detached by pipetting with 300 ll of PBS and fixed with
1% paraformaldehyde (PFA). Samples were analyzed on a
FACSCAN flow cytometer using CellQuestPro software
(Becton Dickinson). Each experiment was done in dupli-
cate. Mean fluorescence intensity of virus binding was
calculated against that of uninfected cells incubated with
mAb 16E4 and secondary antibody.
Inhibition assays and enzyme treatment
For virus binding inhibition assays, cell monolayer grown
in 24-well plates were washed with PBS and then incu-
bated for 1 h at 37 C with neuraminidase at 10 nU per
cell, heparinase I at 25 lU per cell, or heparinase III at
6.25 lU per cell. After three washing steps with PBS, the
virus-binding assay was performed on the cells as descri-
bed above.
To examine the effect of enzymatic treatment of cells on
infection, CMC cells grown in 96-well plates were incu-
bated with one of the enzymes or with a combination of the
enzymes for 1 h at 37 C. Cells were washed with PBS and
infected with different virus strains or variants. Cell via-
bility was measured at 24 h.p.i. using cell proliferation
reagent WST-1 (Roche). Infections were carried out in
quadruplicate with uninfected and treated or infected and
untreated cells as controls. Viability of cells was calculated
as a percentage of the uninfected cell control, and percent
protection was defined as the difference in viability of
infected cells with and without treatment. Statistical anal-
ysis was performed using a one-way ANOVA for repeated
measures, followed by Bonferroni’s post hoc t-test with
significance set at a ‘‘p’’ value less than 0.05.
The effect of soluble heparan sulfate on attachment and
infection was monitored by incubation of the virus with HS
for 1 h at 37 C before binding and infection assays.
Sequence analysis
For sequencing of EMCV strains and variants, infected
BHK-21 cells were used for RNA extraction using an
RNeasy Mini Kit (QIAGEN) according to the manufac-
turer’s instructions. RNA was used for amplification of
EMCV genomic fragments using a one-step RT-PCR kit
(QIAGEN) and EMCV-specific primers (not shown).
Amplified DNA fragments were purified and sequenced
directly on both strands by a dye chain termination method.
Nucleotide sequences were analyzed on an IBM-compati-
ble personal computer using the program Lasergene99
(DNASTAR, USA). The complete capsid nucleotide
sequences of B279/95 and 1086C strains were submitted to
the GenBank database and assigned accession numbers
DQ835184 and DQ835185, respectively.
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Results
Permissiveness of CMC cells to B279/95
and 1086C strains
Human cardiomyocytes have been reported to be permis-
sive to an EMCV MN-30 strain isolated from an aborted
swine foetus [4]. We tested the susceptibility of CMC cells
towards two different strains of EMCV, a highly virulent
porcine myocardial strain (B279/95) and a rat strain
(1086C). Each strain was assayed for virus production and
cell lysis. The CMC cells were infected with the B279/95
strain or the 1086C strain at a high multiplicity of infection,
and virus production at different times postinfection was
determined and compared. Virus production was first
detected 4 h after inoculation, and maximal titers were
reached by 8 h for both strains (Fig. 1a). At 24 h after
infection, the cytopathic effect (CPE) was more pro-
nounced in cells infected with the B279/95 strain than in
1086C-infected cells. This difference in CMC infection
was clearly demonstrated when the MOI was decreased. At
an MOI of 30 PFU per cell, only 20% of B279/95-infected
CMC cells were viable 24 h.p.i., compared to 94% for
1086C-infected cells, whereas the two strains produced
similar CPE on BHK-21 cells (Fig. 1b).
Since the first step in virus infection is the attachment of
viral particles to a cell-surface receptor or coreceptor, we
investigated if the difference in development of cytopathic
effect observed between the two strains resulted from a
difference in their affinity for CMC cells. To answer this
question, the binding properties of B279/95 and 1086C on
CMC cells were examined by flow cytometry and com-
pared. An important difference in the attachment efficien-
cies of B279/95 and 1086C was observed. The data in
Fig. 2 indicate that B279/95 binding on CMC cells is
tenfold greater than 1086C binding, while the two viruses
show similar binding to BHK-21 cells (data not shown).
CMC cell-surface residues involved in B279/95
and 1086C binding and infection
The difference in binding observed between the two
EMCV strains suggests either a difference in receptor type
used that could be more abundant for B279/95, or that the
two strains use the same receptor, but the affinity of strain
1086C for this receptor is weaker. As the involvement of
sialic acids in EMCV binding has been demonstrated pre-
viously for some human cells, such as erythrocytes, HeLa
and K562 cells [14, 29], we investigated the role of sialic
acids in B279/95 and 1086C binding to and infection of
CMC cells. We used flow cytometry analysis and the WST-
1 assay to examine the influence of treatment of cardio-
myocytes by neuraminidase on binding and infection,
respectively. For these studies, it was first necessary to
determine the quantity of neuraminidase that releases a
maximum of cell-surface sialic acids but is not toxic for
cells. We found that treatment 10 nU of neuraminidase per
cell from Vibrio cholerae resulted in 90% cell survival and
reduced cell-surface sialic acid by 50% as measured by
WGA-FITC binding (not shown). More concentrated
neuraminidase dramatically reduced the number of living
cells. Using this concentration, neuraminidase treatment of
CMC cells showed no inhibitory effect on B279/95 binding
or infection. In contrast, 1086C binding was reduced by
more than 60%, and infection, by 27% (p \ 0.05, CI 95 %)
(Fig. 3). These results indicate that cell-surface sialic acids
are involved in attachment and infection of the 1086C
strain but not of the B279/95 strain.
As many viruses, including picornaviruses, have been
found to use heparan sulfate (HS) as a receptor or core-
ceptor, we examined the role of HS in B279/95 attachment
and infection of cardiomyocytes. We assessed B279/95
binding and infection of CMC cells incubated with either
heparinase I, which degrades 2-O- or 6-O-sulfated and
N-sulfated residues in heparin (relative activity 3:1) or with
Fig. 1 EMCV production and cytopathic effect on CMC cells.
(a) Growth curves of strains B279/95 and 1086C on CMC cells. Cells
were infected with virus at an MOI of 1000 PFU per cell. Virus titers
were determined by plaque assays on BHK-21 monolayers. (b) Cyto-
pathic effect induced by strains B279/95 and 1086C on CMC and
BHK-21 cells at 24 h p.i. Cells were infected with virus at different
MOI. At 24 h p.i., cell viability was evaluated by colorimetric assay
using the cell proliferation reagent WST-1. Cell viability was
calculated as a percentage of the uninfected-cell control
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heparinase III, which acts on 6-O-sulfated, N-sulfated or
N-acetylated residues in HS only, or HS. Treatment with
either enzyme resulted in reduction of B279/95 binding in a
dose-dependent manner (Fig. 4a). Incubation of cells with
heparinase I at 25 lU per cell and with heparinase III at
6.25 lU per cell reduced binding by 36% and 42%,
respectively. However, no significant inhibition of infec-
tion was observed after treatment of cells with each
enzyme or a mixture of both (Fig. 5a). Furthermore, when
B279/95 was incubated with soluble heparan sulfate before
infection, a dose-dependent inhibition effect was observed
on virus binding and infection (Fig. 4b; 5b). However,
while 1000 lg of HS ml-1 inhibited B279/95 binding by
95%, infection was inhibited by only 23% (p = 0.002, CI
95 %). These data indicate that HS plays a more profound
role in B279/95 binding than in infection of CMC cells.
To monitor if interaction with HS is a particularity of the
B279/95 strain, we performed similar binding and infection
inhibition assays with the 1086C strain. As shown in
Fig. 4a, 1086C binding was also reduced after treatment of
cells with heparinase. The inhibition with heparinase I was
more important compared to what was observed with the
B279/95 strain: 60% inhibition with heparinase I and 46%
with heparinase III. No significant reduction of infection
was observed when the cells were treated with heparinase I,
heparinase III or both heparinases in comparison to
untreated virus-infected cells (Fig. 5a). Furthermore,
treatment of cells with a combination of neuraminidase and
heparinase I, heparinase III or both heparinases before
infection with 1086C strain resulted in an inhibition of
infection greater than that observed after treatment with
neuraminidase alone. The cell viabilities at 24 h.p.i were
85.71%, 46.95% and 65.90 %, respectively (p \ 0.001, CI
95 %) compared to 31.5% observed after treatment with
neuraminidase alone. This cumulative inhibition effect was
not observed with the B279/95 strain (Fig. 5a). Incubation
of 1086C with HS before infection resulted in reduction of
virus binding and infection in a similar manner to that
observed with the B279/95 strain. Incubation with 1000 lg
of HS ml-1 reduced 1086C binding by 90% (not shown)
and infection by 19% (p = 0.001, CI 95 %) (Fig. 5b).
Fig. 2 Binding of B279/95 and 1086C to CMC cells. CMC cells
were incubated with the indicated strain (MOI of 100), anti-EMCV
MAb 16E4, and goat anti-mouse Ig-FITC for 30 min at 4 C, and
bound virus was detected using a FACSCAN flow cytometer
Fig. 3 Effect of sialidase on EMCV binding and infection. CMC
cells (106) were treated with 10 nU of neuraminidase from Vibrio
cholerae per cell for 1 h at 37 C prior to analysis of virus binding
(a and b) and infection (c) (MOI 1000). Bound virus was analyzed by
flow cytometry, and CPE was analyzed by the WST-1 assay. Binding
(a and b) and infection of cells (c) were calculated relative to binding
and infection in the absence of sialidase treatment
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Amino acid residues involved in EMCV binding
and infection of CMC cells
In order to identify the amino acid residues that may play a
role in EMCV binding and infection, we determined and
compared the capsid coding region of the two EMCV
strains. Sequence comparison revealed a difference in
seven amino acid residues between 1086C and B279/95,
three in VP1 (K54E, N64T, H81Y), two in VP2 (V141A,
K145R) and two in VP3 (D60N, S92T). None of the
mutations were located in the ‘‘pit’’, the putative receptor-
binding site of EMCV. However, with the exception of
amino acid S92 of VP3, all of these residues were well
exposed on the capsid surface (Fig. 6), suggesting their
possible interaction with cell-surface residues.
Furthermore, we isolated 14 variants of the 1086C strain
on BHK-21 cells and compared their binding to cardio-
myocytes and their ability to induce cytolysis. The data
revealed that the variants can be divided into two groups:
group I (variants Cl1, Cl2, Cl7, Cl9), whose binding was
equivalent to that of the initial 1086C strain and induced a
total destruction of the cell monolayer by 24 h.p.i., and
group II (Cl3, Cl4, Cl5, Cl6, Cl8, Cl10, Cl11, Cl12, Cl13,
Cl14), which showed less binding and were less virulent
(data not shown). One variant from the group I (Cl7) and
one from group II (Cl3) were selected, and their binding
characteristics were analyzed. In the absence of enzymatic
treatment, the Cl7 variant bound 10-fold more efficiently
than the Cl3 variant (Fig. 7a) and induced more than 75%
cell destruction at 24 h.p.i., compared to 34% for variant
Cl3 (Fig. 7b). The binding and infection of variant Cl3 was
not significantly (p [ 0.05) inhibited by treatment of cells
with neuraminidase, whereas the attachment of variant Cl7
was reduced by more than 70%, and infection, by 47%
(p \ 0.001, CI 95 %) (Fig. 7a, b).
In order to identify the amino acid residues that may be
involved in attachment of the Cl7 variant to sialic acid, we
determined and compared the capsid amino acid sequences
of the two variants. Only one amino acid residue situated in
the VP1 protein at position 231 was different between the
Fig. 4 Effect of heparinase and heparan sulfate on EMCV binding.
a) CMC cells (106) were treated with heparinase I (5 and 25 lU/cell)
or III (1.25 and 6.25 lU/cell) for 1 h at 37 C prior to virus binding
(MOI 1000). Bound virus was analyzed by flow cytometry, and
inhibition of binding was calculated relative to binding in the absence
of enzyme treatment. b) Virus was incubated with increasing
concentrations of HS for 1 h at 37 C before binding of CMC cells
(MOI of 1000)
Fig. 5 Effect of heparinase and sialidase on EMCV infection. a)
CMC cells (106) were treated with heparinase I (25 lU lU/cell),
heparinase III (6.25 lU lU/cell), neuraminidase (10 nU per cell), or a
combination of the enzymes for 1 h at 37 C prior to infection with
B279/95 or 1086C (MOI 1000). b) Virus was incubated with
increasing concentrations of HS for 1 h at 37 C before infection of
CMC cells (MOI of 1000). CPE was analyzed by the WST-1 assay,
and inhibition of infection was calculated relative to infection in the
absence of enzyme treatment
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two variants. This residue was a lysine in variant Cl7 and
an arginine in variant Cl3. It is localized at the surface of
the capsid and outside the putative receptor site (Fig. 6).
This mutation was also found in all other non-virulent
variants (not shown).
Discussion
The data reported here show that human cardiomyocytes
are permissive to a highly virulent myocardial pig strain
(B279/95) of EMCV, and infection is associated with cell
destruction. These results are in accordance with the data
reported by Brewer et al. [4], which demonstrated the
permissiveness of CMC cells to an abortive pig strain of
EMCV (MN-30). The strain B279/95 replicated in CMC
cells and induced complete cytolysis at 24 h.p.i. However,
the cytopathic effects were dependent on the MOI used,
whereas for BHK-21 cells, a very low MOI was sufficient
to induce complete lysis. One explanation for this differ-
ence between the two cell lines is that EMCV is adapted to
BHK-21 cells, since it is produced in them. Another
explanation may be related to interferon. BHK-21 cells do
not produce interferon, which is one of the first defenses of
cells against viruses. This might explain the intensity of the
cytopathic effect on BHK-21 monolayers. In contrast, for
cardiomyocytes, the first infected cells can synthetize
interferon in order to reduce infection of the adjacent cells.
This is also one of the reasons why BHK-21 cells are often
used for the production of many viruses. Moreover, BHK-
21 cells were obtained from a hamster, and rodents are a
reservoir for EMCV. Therefore, the high sensitivity of
these cells could also be related to the species tropism.
Strain B279/95 was isolated from a piglet that died of
myocarditis [20]. Consequently, the cytolysis and signifi-
cant viral production observed in cardiomyocytes may be
expected. However, this strain can infect and produce
cytopathic effects in a variety of human cells, including
primary astrocytes and renal epithelial cells (not shown).
The findings of Brewer et al. [4] suggest that strain B279/
95 is more virulent than MN-30. Brewer et al. have shown
that CMC cells are permissive to strain MN-30, while
human renal epithelial cells are resistant. These results
indicate that EMCV strains may differ in their ability to
infect human cells. From a medical point of view, this
B279/95 strain could present a high risk for humans in the
case of pig-to-human xenotransplantation if we consider
the routine immunosuppression of recipients.
Our data also show that a strain isolated from a rat
infects human cardiomyocytes and induces cell lysis.
However, this strain is less virulent than the B279/95
strain, since a high MOI is needed to achieve complete cell
lysis. This high MOI is certainly not encountered under in
vivo conditions, and this strain would probably not be
infectious under such conditions. However, in order to gain
Fig. 6 Amino acid residues
involved in EMCV binding and
infection. Residues are shown
on the pentamer (left) and the
protomer (right) in a space-
filling model generated with
VIPERdb and Swiss-PdB
software based on structural
data obtained with Mengo virus
[22]. Residue 1: mutation
between Cl3 and Cl7 variants of
1086C strain. Residues 2 to 7:
mutations between strains
B279/95 and 1086C. VP1 is
indicated in blue, VP2 in green,
VP3 in red and VP4 in grey
Fig. 7 Effect of sialidase on Cl3 and Cl7 binding (a) and infection
(b). CMC cells (106) were treated with 10 nU of neuraminidase per
cell for 1 h at 37 C prior to virus binding (a) and infection (b) (MOI
1000). Bound virus was analyzed by flow cytometry, and CPE was
analyzed using the WST-1 assay
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further insight into the mechanisms involved in EMCV
infection of human cells by comparing the two strains, we
carried on the infection studies using high MOI. The low
virulence of the 1086C strain is probably due, at least in
part, to its low efficiency of binding to CMC cells, which
was 10-fold lower than that of B279/95. The binding dif-
ferences observed between the two strains suggest either a
difference in receptor type used, being more abundant for
B279/95, or that the two strains use the same receptor
present on CMC cells but the affinity of strain 1086C for
this receptor is weaker.
The initial step in virus infection is often the binding to
an attachment molecule, a coreceptor, followed by binding
to a high-affinity entry protein. EMC virus attachment to
permissive human cell lines K562 and HeLa and non-
permissive human erythrocytes has been reported to be
mediated by a cell-surface sialic acid [14, 29]. Here, we
showed that neuraminidase treatment of primary human
cardiomyocytes prior to binding assays reduced the
attachment and infection of strain 1086C but not of strain
B279/95. This result indicates that cell-surface sialic acid
residues mediate attachment and infection of 1086C on
cardiomyocytes, whereas the attachment of B279/95 to
these cells is independent of sialic acid. Furthermore,
analysis based on soluble HS inhibition of attachment and
infection and enzymatic removal of HS established that the
two strains are able to use HS for binding to CMC cells.
Since these treatments did not significantly reduce virus
infection, this suggests that the HS binding is not abso-
lutely necessary for virus infection. However, the fact that
treatment of cells with a combination of heparinase and
neuraminidase increased the inhibition of 1086C infection
in comparison to treatment with neuraminidase alone
suggests that HS binding is cooperatively linked to the
process of 1086C infection. Infection by B279/95 was not
inhibited by neuraminidase or heparinases or a combina-
tion of both, suggesting that this strain uses a different
coreceptor to initiate infection or binds directly to a protein
entry receptor. These results imply the existence of at least
two different kinds of binding before the entry of EMCV
into human cardiomyocytes. A similar difference in the
binding properties of different strains has already been
reported for another cardiovirus. Whereas persistent strains
of Theiler’s virus (BeAn and DA) bind to sialic acid, the
highly virulent strain GDVII uses heparan sulfate to bind
and infect permissive cells [32]. It is uncertain if there is a
correlation between the nature of binding of EMCV strains
and their virulence. Further in vivo experiments are needed
to answer this question.
Genetic analysis of the capsid coding region showed
seven amino acid differences between the B279/95 and
1086C strains, three in VP1 (K54E, N64T and H81Y)
and two in VP2 (V141A and K145R) and VP3 (D60N and
S92T). Since 95% of the amino acid sequences of EMCV
and Mengo virus are identical, it seems reasonable to
predict that the three-dimensional structure is conserved
between the two viruses. Considering the three-dimen-
sional structure of the Mengo virus capsid [22], with the
exception of mutation S92T, all of the amino acids that
differ between the two EMCV strains are exposed on the
outer surface, suggesting a role of these residues in EMCV
binding to human cells. Since none of these amino acids
are located in or near the putative receptor-binding site,
which is a depression called a ‘‘pit’’ between VP1 and VP3,
it is possible that these amino acids interact with a core-
ceptor molecule rather than with the receptor.
Amino acid 64 of VP1 is located in the bB-bC loop. For
Mengo virus, this region has been reported to constitute a
recognition site for neutralizing antibodies [18]. Indeed,
mutants of Mengo virus that were able to escape neutral-
ization by a selected neutralizing monoclonal antibody
have been found to have mutations in this region: K49Q
and N62D of VP1. For EMCV, the mutation N62D has
been observed for the B279/95 strain after attenuation of
the virus by serial passages on BHK-21 cells [8]. Fur-
thermore, diabetogenic (PV2) and non-diabetogenic vari-
ants (PV7) of EMCV have been reported to differ by one
mutation at residue 63 of the VP1 (Q63E/K) [25]. These
results suggest that amino acid 64 may contribute to
determining EMCV tropism and virulence.
Other mutations affecting the surface of the capsid are
localized in VP2 puff B (V141A and K145R) and in VP3
‘‘knob’’ (D60N). These two regions are localized on the
surface of Mengo virus and constitute recognition sites 1
and 2, respectively, for neutralizing antibodies. Mengo
virus mutants selected to escape chosen neutralization
monoclonal antibodies have shown mutations in VP2
(N144S and R145K) and in VP3 (A61V) [18]. For Theil-
er’s virus, it was shown that mutations responsible for
adaptation to L929 cells occurred in two clusters of amino
acids known to be part of neutralization epitopes [15]. By
analogy, it is probable that the regions corresponding to the
neutralization sites of EMCV also contribute to the inter-
action of the virus with cell-surface molecules and influ-
ence virus tropism.
Analysis of variants isolated from the 1086C strain
revealed that variants showing a difference in their ability to
use sialic acid for binding to cardiomyocytes differ by one
amino acid in the capsid coding region at residue 231 of the
VP1 protein. All of the variants that used sialic acid had a
lysine residue rather than arginine. These results, which
were obtained due to the use of a high MOI, confirmed that
strain 1086C is sialic acid dependent. This strain is a mix-
ture of variants that can adsorb efficiently to cardiomyo-
cytes using sialic acid (group I) and variants that do not bind
specifically to cardiomyocytes because they do not bind to
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sialic acid (group II). These results also support a role of
residue K231 of VP1 in the interaction of EMCV with sialic
acid residues and are consistent with an observation previ-
ously reported for Mengo virus. Mengo virus mutants that
had lost their ability to hemagglutinate human erythrocytes
have been found to have two consecutive mutations in VP1:
K231R and P232S [23]. The fact that agglutination of
human erythrocytes by Mengo virus is dependent on the
presence of sialic acid on the erythrocyte surface [3] sug-
gests that residues K231 and P232 of VP1 are involved in
the interaction of the virus with sialic acid. As for Mengo
virus, the attachment molecule for EMCV on human
erythrocytes is glycophorin A, the major sialoglycoprotein
of the erythrocyte surface, and sialic acid is the component
involved in virus binding. Since the capsid sequences of the
two viruses are well conserved, it is likely that same
residues are used by the two viruses for interaction with cell-
surface sialic acid. The non-erythrocyte origin of cardio-
myocytes suggests the involvement of another cell-surface
molecule other than glycophorin A in EMCV binding to those
cells. EMCV virus attachment to the permissive human cell
lines HeLa and K562 has been reported to be mediated by a
cell-surface 70-kDa sialoglycoprotein [14]. Whether this
protein is also involved in the attachment of EMCV to human
cardiomyocytes remains to be established.
In conclusion, our results indicate that a pig myocardial
strain and a rat strain of EMCV productively infect primary
human cardiomyocytes and induce cell destruction. It also
shows flexibility in receptor usage for EMCV. In addition
to sialic acid, cell-surface heparan sulfate appears to con-
tribute to the binding of EMCV to human cardiomyocytes
but does not seem to be necessary for infection. Since
attachment and entry of EMCV are still poorly understood,
a possible role for heparan sulfate during cell infection
should be taken in consideration in further studies. Fur-
thermore, analysis of B279/95 infection suggests that this
strain uses an alternative attachment mechanism that
requires an interaction with neither sialic acid nor heparan
sulfate. The capsid mutations identified in these experi-
ments will help to understand better the structural
requirements for EMCV attachment to human cells.
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